{"id":"https://openalex.org/W3005583371","doi":"https://doi.org/10.1634/theoncologist.2020-0034","title":"Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation","display_name":"Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation","publication_year":2020,"publication_date":"2020-02-12","ids":{"openalex":"https://openalex.org/W3005583371","doi":"https://doi.org/10.1634/theoncologist.2020-0034","mag":"3005583371","pmid":"https://pubmed.ncbi.nlm.nih.gov/32048771","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7356710"},"language":"en","primary_location":{"id":"doi:10.1634/theoncologist.2020-0034","doi":"https://doi.org/10.1634/theoncologist.2020-0034","is_oa":false,"landing_page_url":"https://doi.org/10.1634/theoncologist.2020-0034","pdf_url":null,"source":{"id":"https://openalex.org/S15523509","display_name":"The Oncologist","issn_l":"1083-7159","issn":["1083-7159","1549-490X"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316295","host_organization_name":"AlphaMed Press","host_organization_lineage":["https://openalex.org/P4310316295"],"host_organization_lineage_names":["AlphaMed Press"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Oncologist","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7356710","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070734531","display_name":"Sandip Pravin Patel","orcid":"https://orcid.org/0000-0002-8387-4840","observed_orcids":["https://orcid.org/0000-0002-8387-4840","https://orcid.org/0000-0002-4954-4944"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sandip Pravin Patel","raw_affiliation_strings":["Moores Cancer Center, University of California at San Diego Health-La Jolla, La Jolla, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moores Cancer Center, University of California at San Diego Health-La Jolla, La Jolla, California, USA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110734103","display_name":"Suchita Pakkala","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Suchita Pakkala","raw_affiliation_strings":["Emory Winship Cancer Institute, Atlanta, Georgia, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Emory Winship Cancer Institute, Atlanta, Georgia, USA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002170706","display_name":"Nathan A. Pennell","orcid":"https://orcid.org/0000-0002-1458-0064","observed_orcids":["https://orcid.org/0000-0002-1458-0064"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nathan A. Pennell","raw_affiliation_strings":["Cleveland Clinic, Cleveland, Ohio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic, Cleveland, Ohio, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051283101","display_name":"Karen L. Reckamp","orcid":"https://orcid.org/0000-0002-9213-0325","observed_orcids":["https://orcid.org/0000-0002-9213-0325"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]},{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen L. Reckamp","raw_affiliation_strings":["City of Hope Comprehensive Cancer Center, Duarte, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"City of Hope Comprehensive Cancer Center, Duarte, California, USA","institution_ids":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017925719","display_name":"Silvana Lanzalone","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142120","display_name":"Pfizer (Italy)","ror":"https://ror.org/03htt2d69","country_code":"IT","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210142120"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Silvana Lanzalone","raw_affiliation_strings":["Pfizer S.R.L., Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer S.R.L., Milan, Italy","institution_ids":["https://openalex.org/I4210142120"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083634538","display_name":"Anna Polli","orcid":"https://orcid.org/0009-0003-5440-6129","observed_orcids":["https://orcid.org/0009-0003-5440-6129"]},"institutions":[{"id":"https://openalex.org/I4210142120","display_name":"Pfizer (Italy)","ror":"https://ror.org/03htt2d69","country_code":"IT","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210142120"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Anna Polli","raw_affiliation_strings":["Pfizer S.R.L., Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer S.R.L., Milan, Italy","institution_ids":["https://openalex.org/I4210142120"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084565053","display_name":"Jamal Tarazi","orcid":"https://orcid.org/0000-0002-5452-2061","observed_orcids":["https://orcid.org/0000-0002-5452-2061"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jamal Tarazi","raw_affiliation_strings":["Pfizer Oncology, San Diego, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Oncology, San Diego, California, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5009495617","display_name":"Francisco Robert-Vizcarrondo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Francisco Robert-Vizcarrondo","raw_affiliation_strings":["University of Alabama at Birmingham, Birmingham, Alabama, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham, Birmingham, Alabama, USA","institution_ids":["https://openalex.org/I32389192"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5070734531"],"corresponding_institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"],"apc_list":{"value":1500,"currency":"USD","value_usd":1500},"apc_paid":null,"fwci":2.795,"has_fulltext":false,"cited_by_count":34,"citation_normalized_percentile":{"value":0.92870348,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"25","issue":"7","first_page":"562","last_page":"e1012"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/crizotinib","display_name":"crizotinib","score":1.0},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":1.0},{"id":"https://openalex.org/keywords/alk-positive-non-small-cell-lung-cancer","display_name":"ALK-positive non-small cell lung cancer","score":0.8899999856948853},{"id":"https://openalex.org/keywords/alk-rearrangement","display_name":"ALK rearrangement","score":0.7929999828338623},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8119999766349792},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7009999752044678},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9190000295639038},{"id":"https://openalex.org/keywords/transaminase-elevation","display_name":"transaminase elevation","score":0.8450000286102295},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7540000081062317},{"id":"https://openalex.org/keywords/second-generation-alk-inhibitors","display_name":"second-generation ALK inhibitors","score":0.7940000295639038}],"concepts":[{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.9804295301437378},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.8059351444244385},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7900586724281311},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.7163521647453308},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6827509999275208},{"id":"https://openalex.org/C2778347629","wikidata":"https://www.wikidata.org/wiki/Q4652380","display_name":"ALK inhibitor","level":5,"score":0.6700363159179688},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6302472352981567},{"id":"https://openalex.org/C2779750558","wikidata":"https://www.wikidata.org/wiki/Q21011233","display_name":"Ceritinib","level":5,"score":0.5439527034759521},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5338121056556702},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4360886812210083},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.39558035135269165},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3434722423553467},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.09498631954193115},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000077547","descriptor_name":"Crizotinib","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000077547","descriptor_name":"Crizotinib","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000077548","descriptor_name":"Anaplastic Lymphoma Kinase","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D015321","descriptor_name":"Gene Rearrangement","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020794","descriptor_name":"Receptor Protein-Tyrosine Kinases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1634/theoncologist.2020-0034","doi":"https://doi.org/10.1634/theoncologist.2020-0034","is_oa":false,"landing_page_url":"https://doi.org/10.1634/theoncologist.2020-0034","pdf_url":null,"source":{"id":"https://openalex.org/S15523509","display_name":"The Oncologist","issn_l":"1083-7159","issn":["1083-7159","1549-490X"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316295","host_organization_name":"AlphaMed Press","host_organization_lineage":["https://openalex.org/P4310316295"],"host_organization_lineage_names":["AlphaMed Press"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Oncologist","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7356710","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7356710","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncologist","raw_type":"Text"},{"id":"pmid:32048771","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32048771","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The oncologist","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:7356710","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7356710","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncologist","raw_type":"Text"},"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":9,"referenced_works":["https://openalex.org/W2071865120","https://openalex.org/W2099530756","https://openalex.org/W2400514548","https://openalex.org/W2527905628","https://openalex.org/W2624310346","https://openalex.org/W2803802743","https://openalex.org/W2810228459","https://openalex.org/W2811121118","https://openalex.org/W2890230728"],"related_works":["https://openalex.org/W2791886669","https://openalex.org/W954457330","https://openalex.org/W2972079805","https://openalex.org/W2257265893","https://openalex.org/W2902475867","https://openalex.org/W2809677973","https://openalex.org/W2998884390","https://openalex.org/W37749742","https://openalex.org/W2416538814","https://openalex.org/W2767655639"],"abstract_inverted_index":{"LESSONS":[0],"LEARNED:":[1],"This":[2,126],"study":[3,127,293],"evaluating":[4],"first-line":[5,140],"crizotinib":[6,108,136,157,195,203],"plus":[7,137],"pembrolizumab":[8,138,163,212],"in":[9,33,84,100,142,243,249,266,272,291],"patients":[10,45,74,143,180,230,245],"with":[11,144,156,208],"anaplastic":[12,115],"lymphoma":[13,116],"kinase":[14,117],"(ALK)-positive":[15],"advanced":[16,119],"non-small":[17,120],"cell":[18,121],"lung":[19,122],"cancer":[20,123],"(NSCLC)":[21],"was":[22,171,221,226,284],"terminated":[23],"early":[24,292],"because":[25,68,287],"increased":[26],"availability":[27],"of":[28,44,69,73,79,89,114,135,194,211],"second-generation":[29],"ALK":[30,92],"inhibitors":[31],"resulted":[32,290],"difficulty":[34],"identifying":[35],"and":[36,94,131,162,253,257,268,275],"accruing":[37],"eligible":[38],"patients.":[39],"In":[40],"the":[41,50,70,76,112,129,209],"small":[42,71],"number":[43,72],"enrolled,":[46],"elevated":[47],"transaminases":[48],"were":[49,59,148,181,231],"most":[51],"common":[52],"treatment-related":[53],"toxicity.":[54,223],"No":[55],"other":[56],"relevant":[57],"toxicities":[58,241],"observed.":[60],"Although":[61],"no":[62],"definitive":[63],"conclusions":[64],"could":[65],"be":[66,88],"drawn":[67],"studied,":[75],"higher":[77],"frequency":[78],"severe":[80],"transaminase":[81],"increases":[82,248,271],"noted":[83],"this":[85],"sample":[86],"should":[87],"concern":[90],"if":[91],"inhibitor":[93,96],"PD-L1/PD-1":[95],"combinations":[97],"are":[98],"tested":[99],"future":[101],"studies.":[102],"BACKGROUND:":[103],"Previous":[104],"research":[105],"suggests":[106],"single-agent":[107],"is":[109],"efficacious":[110],"for":[111],"treatment":[113],"(ALK)-rearranged":[118],"(NSCLC).":[124],"METHODS:":[125],"evaluated":[128],"safety":[130],"preliminary":[132],"antitumor":[133],"activity":[134,225],"as":[139],"therapy":[141],"ALK-rearranged":[145],"NSCLC.":[146],"Patients":[147],"initially":[149],"treated":[150],"at":[151,183,234,238,261,277],"dose":[152,186,283],"level":[153,187,189],"0":[154],"(DL0)":[155],"250":[158,197,204],"mg":[159,165,198,205,214],"twice":[160,199,206],"daily":[161,207],"200":[164,213],"every":[166,215],"3":[167,172,192,216,247,259,264,270],"weeks":[168,193],"(cycle":[169],"duration":[170],"weeks).":[173,217],"If":[174],"a":[175,184],"dose-limiting":[176,222],"toxicity":[177],"occurred,":[178],"subsequent":[179],"enrolled":[182],"lower":[185],"(dose":[188],"-1":[190],"[DL-1]:":[191],"monotherapy":[196],"daily,":[200],"followed":[201],"by":[202],"addition":[210],"The":[218,280],"primary":[219],"endpoint":[220],"Antitumor":[224],"assessed.":[227],"RESULTS:":[228],"Nine":[229],"enrolled:":[232],"two":[233],"DL0,":[235],"then":[236],"seven":[237],"DL-1.":[239],"Dose-limiting":[240],"occurred":[242],"four":[244],"(grade":[246],"alanine":[250],"aminotransferase":[251,255],"[ALT]":[252],"aspartate":[254],"[AST]":[256],"grade":[258,263,269],"fatigue":[260],"DL0;":[262],"increase":[265],"ALT":[267,274],"both":[273],"AST":[276],"DL-1).":[278],"CONCLUSION:":[279],"maximum":[281],"tolerated":[282],"not":[285],"determined":[286],"slow":[288],"accrual":[289],"termination.":[294]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":6}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2020-02-24T00:00:00"}